Suchergebnisse - "Lim, Chay Ngee"

PubPharm (20)

1

Using Mitra sampling to support first-in-human pharmacokinetic evaluations for PF-07059013

enthalten in: Bioanalysis | 2023

von Lee, K. | Wan, K. | Barricklow, J. | +6

2

A Phase 1 first-in-human study of the safety, tolerability, and pharmacokinetics of the ROBO2 fusion protein PF-06730512 in healthy participants

enthalten in: Pharmacology research & perspectives | 2021

von Lim, C. | Kantaridis, C. | Huyghe, I. | +3

3

PODO : Trial Design: Phase 2 Study of PF-06730512 in Focal Segmental Glomerulosclerosis

enthalten in: Kidney international reports | 2021

von Beck, L. | Berasi, S. | Copley, J. | +6

4

A Phase 1 first‐in‐human study of the safety, tolerability, and pharmacokinetics of the ROBO2 fusion protein PF‐06730512 in healthy participants

enthalten in: Pharmacology Research & Perspectives | 2021

von Lim, C. | Kantaridis, C. | Huyghe, I. | +3

5

Erratum. Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes : 12- and 24-Week Phase 2 Studies. Diabetes Care 2016;39:1241-1249

enthalten in: Diabetes care | 2017

von Kazda, C. | Ding, Y. | Kelly, R. | +10

ErratumFor: Diabetes Care. 2016 Jul;39(7):1241-9. - PMID 26681715

6

Phxnlme : An R package that facilitates pharmacometric workflow of Phoenix NLME analyses

enthalten in: Computer methods and programs in biomedicine | 2017

von Lim, C. | Liang, S. | Feng, K. | +4

7

Phxnlme: An R package that facilitates pharmacometric workflow of Phoenix NLME analyses

enthalten in: Computer methods and programs in biomedicine | 2017

von Lim, C. | Liang, S. | Feng, K. | +4

8

Response to Comment on Kazda et al. Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes : 12- and 24-Week Phase 2 Studies. Diabetes Care 2016;39:1241-1249

enthalten in: Diabetes care | 2016

von Kazda, C. | Ding, Y. | Kelly, R. | +10

CommentOn: Diabetes Care. 2016 Jul;39(7):1241-9. - PMID 26681715

9

Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes : 12- and 24-Week Phase 2 Studies

enthalten in: Diabetes care | 2016

von Kazda, C. | Ding, Y. | Kelly, R. | +10

CommentIn: Diabetes Care. 2016 Jul;39(7):1075-7. - PMID 27330122

10

Pharmacokinetic-Pharmacodynamic Modeling of Intravenous and Oral Topiramate and Its Effect on the Symbol-Digit Modalities Test in Adult Healthy Volunteers

enthalten in: Journal of clinical pharmacology | 2016

von Lim, C. | Birnbaum, A. | Brundage, R. | +4